Palisade Bio (PALI) Depreciation & Amortization (CF) (2010 - 2025)
Palisade Bio (PALI) reported Depreciation & Amortization (CF) of $1000.0 for Q3 2025, little changed year-over-year from $1000.0 in Q3 2024, and little changed on a QoQ basis from $1000.0 in Q2 2025.
Palisade Bio (PALI) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $1000.0 in Q3 2025.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $2000.0 (down 33.33% YoY) and the FY2025 annual result came in at $3000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) was little changed at $1000.0 in Q3 2025 per PALI's latest filing, from $1000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2000.0 in Q4 2022 and bottomed at $1000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $1000.0 (2021), against an average of $1153.8.
- Peak annual rise in Depreciation & Amortization (CF) reached 103.56% in 2021, while the deepest fall reached 96.56% in 2021.
- Tracing PALI's Depreciation & Amortization (CF) over 5 years: stood at $1000.0 in 2021, then surged by 100.0% to $2000.0 in 2022, then tumbled by 50.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then changed by 0.0% to $1000.0 in 2025.
- Per Business Quant, the three latest PALI Depreciation & Amortization (CF) figures stand at $1000.0 (Q3 2025), $1000.0 (Q2 2025), and $1000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 2,000.00 |
| Dec 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | -28,078.00 |
| Jun 30, 2020 | -28,078.00 |
| Mar 31, 2020 | 29,078.00 |
| Mar 31, 2020 | 29,078.00 |
| Dec 31, 2019 | 30,124.00 |
| Dec 31, 2019 | 30,124.00 |
| Sep 30, 2019 | 36,584.00 |
| Sep 30, 2019 | 36,584.00 |
| Jun 30, 2019 | 37,330.00 |
| Jun 30, 2019 | 37,330.00 |
| Mar 31, 2019 | 39,821.00 |
| Mar 31, 2019 | 39,821.00 |
| Dec 31, 2018 | 25,339.00 |
| Dec 31, 2018 | 25,339.00 |
| Sep 30, 2018 | 46,152.00 |
| Sep 30, 2018 | 46,152.00 |
| Jun 30, 2018 | 46,938.00 |
| Jun 30, 2018 | 46,938.00 |
| Mar 31, 2018 | 67,374.00 |
| Mar 31, 2018 | 67,374.00 |
| Dec 31, 2017 | 55,619.00 |
| Dec 31, 2017 | 55,619.00 |
| Sep 30, 2017 | 53,003.00 |
| Sep 30, 2017 | 53,003.00 |
| Jun 30, 2017 | 68,381.00 |
| Jun 30, 2017 | 68,381.00 |
| Mar 31, 2017 | 112,205.00 |
| Mar 31, 2017 | 112,205.00 |
| Dec 31, 2016 | 62,434.00 |
| Dec 31, 2016 | 62,434.00 |
| Sep 30, 2016 | 97,576.00 |
| Sep 30, 2016 | 97,576.00 |
| Jun 30, 2016 | 92,031.00 |
| Jun 30, 2016 | 92,031.00 |
| Mar 31, 2016 | 85,467.00 |
| Mar 31, 2016 | 85,467.00 |
| Dec 31, 2015 | 90,062.00 |
| Dec 31, 2015 | 90,062.00 |
| Sep 30, 2015 | 88,022.00 |
| Sep 30, 2015 | 88,022.00 |
| Jun 30, 2015 | 83,603.00 |
| Jun 30, 2015 | 83,603.00 |
| Mar 31, 2015 | 83,773.00 |
| Mar 31, 2015 | 83,773.00 |
| Dec 31, 2014 | 88,409.00 |
| Dec 31, 2014 | 88,409.00 |
| Sep 30, 2014 | 83,001.00 |
| Sep 30, 2014 | 83,001.00 |
| Jun 30, 2014 | 86,732.00 |
| Jun 30, 2014 | 86,732.00 |
| Mar 31, 2014 | 90,488.00 |
| Mar 31, 2014 | 90,488.00 |
| Dec 31, 2013 | 62,734.00 |
| Dec 31, 2013 | 62,734.00 |
| Sep 30, 2013 | 81,393.00 |
| Sep 30, 2013 | 81,393.00 |
| Jun 30, 2013 | 50,505.00 |
| Jun 30, 2013 | 50,505.00 |
| Mar 31, 2013 | 50,093.00 |
| Mar 31, 2013 | 50,093.00 |
| Dec 31, 2012 | 46,989.00 |
| Dec 31, 2012 | 46,989.00 |
| Sep 30, 2012 | 87,908.00 |
| Sep 30, 2012 | 87,908.00 |
| Jun 30, 2012 | 41,300.00 |
| Jun 30, 2012 | 41,300.00 |
| Mar 31, 2012 | 34,946.00 |
| Mar 31, 2012 | 34,946.00 |
| Dec 31, 2011 | 37,502.00 |
| Dec 31, 2011 | 37,502.00 |
| Sep 30, 2011 | 64,285.00 |
| Sep 30, 2011 | 64,285.00 |
| Jun 30, 2011 | 59,971.00 |
| Jun 30, 2011 | 59,971.00 |
| Mar 31, 2011 | 25,293.00 |
| Mar 31, 2011 | 25,293.00 |
| Dec 31, 2010 | 28,755.00 |
| Dec 31, 2010 | 28,755.00 |
| Sep 30, 2010 | 42,333.00 |
| Sep 30, 2010 | 42,333.00 |
| Jun 30, 2010 | 30,601.00 |
| Jun 30, 2010 | 30,601.00 |